Recovery Report: Silgan Holdings Inc.'s Recovery Rating Profile Jul 11

  • ID: 2088218
  • July 2011
  • Standard & Poors
1 of 3

Standard & Poor's Ratings Services has updated its issue-level and recovery ratings on Stamford, Conn.-based consumer goods packaging manufacturer Silgan Holdings Inc. to reflect the increase of its proposed US$ term loan A tranche to $520 million from $400 million (see table 1). The company will use the proceeds of the proposed $1.8 billion senior secured credit facilities to refinance existing senior secured debt, to provide for working capital and general corporate purposes. Our simulated default scenario assumes a default year of 2016, based on a significant decline in revenues due to the loss of key customers and margin compression from heightened competition and rising costs. The company's pro forma debt structure consists of the following facilities: $800 million revolving...

Companies mentioned in this report are: Silgan Holdings Inc.,Silgan Plastics Canada Inc.

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

Silgan Holdings Inc.,Silgan Plastics Canada Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our


Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.